Cynthia Levy

9.7k total citations · 4 hit papers
179 papers, 4.4k citations indexed

About

Cynthia Levy is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Cynthia Levy has authored 179 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Hepatology, 96 papers in Epidemiology and 69 papers in Surgery. Recurrent topics in Cynthia Levy's work include Liver Diseases and Immunity (126 papers), Liver Disease Diagnosis and Treatment (89 papers) and Pediatric Hepatobiliary Diseases and Treatments (47 papers). Cynthia Levy is often cited by papers focused on Liver Diseases and Immunity (126 papers), Liver Disease Diagnosis and Treatment (89 papers) and Pediatric Hepatobiliary Diseases and Treatments (47 papers). Cynthia Levy collaborates with scholars based in United States, Canada and United Kingdom. Cynthia Levy's co-authors include Keith D. Lindor, Christopher L. Bowlus, Marlyn J. Mayo, James L. Boyer, Paul Angulo, Gideon M. Hirschfield, Nicholas F. LaRusso, David Jones, James Lymp and Gregory J. Gores and has published in prestigious journals such as New England Journal of Medicine, Blood and Annals of Internal Medicine.

In The Last Decade

Cynthia Levy

162 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases

2018 502 citations Keith D. Lindor, Christopher L. Bowlus et al. Hepatology profile →
EASL Clinical Practice Guidelines on sclerosing cholangitis

2022 175 citations Annika Bergquist, Cynthia Levy et al. Journal of Hepatology profile →
Primary biliary cholangitis: Epidemiology, prognosis, and treatment

2023 66 citations Cynthia Levy et al. Hepatology Communications profile →
Primary sclerosing cholangitis

2025 13 citations Annika Bergquist, Cynthia Levy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cynthia Levy United States	37	3.2k	2.5k	2.1k	894	846	179	4.4k
Andrea Crosignani Italy	36	2.5k 0.8×	2.3k 0.9×	1.0k 0.5×	769 0.9×	493 0.6×	90	3.8k
Atsushi Tanaka Japan	37	2.9k 0.9×	2.5k 1.0×	1.9k 0.9×	490 0.5×	817 1.0×	197	4.5k
Henk R. van Buuren Netherlands	37	3.5k 1.1×	2.8k 1.1×	2.6k 1.2×	745 0.8×	1.1k 1.3×	134	5.0k
Annika Bergquist Sweden	42	3.9k 1.2×	2.4k 1.0×	3.3k 1.6×	776 0.9×	2.1k 2.5×	149	5.8k
Maha Guindi Canada	34	1.9k 0.6×	2.1k 0.8×	1.2k 0.6×	696 0.8×	541 0.6×	115	3.9k
Denise M. Harnois United States	34	3.2k 1.0×	2.2k 0.9×	2.6k 1.2×	944 1.1×	1.1k 1.3×	110	5.1k
Raoul Poupon France	43	5.7k 1.8×	5.0k 2.0×	3.2k 1.5×	1.5k 1.7×	839 1.0×	90	7.9k
Nedim Hadžić United Kingdom	39	1.1k 0.3×	1.0k 0.4×	2.5k 1.2×	572 0.6×	1.4k 1.6×	140	4.9k
Kenji Takenaka Japan	37	2.1k 0.7×	1.2k 0.5×	1.6k 0.8×	1.2k 1.3×	705 0.8×	139	4.3k
Ulrika Broomé Sweden	48	4.4k 1.4×	2.8k 1.1×	3.4k 1.6×	807 0.9×	2.3k 2.7×	101	6.7k

Countries citing papers authored by Cynthia Levy

Since Specialization

Citations

This map shows the geographic impact of Cynthia Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cynthia Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cynthia Levy more than expected).

Fields of papers citing papers by Cynthia Levy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cynthia Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cynthia Levy. The network helps show where Cynthia Levy may publish in the future.

Co-authorship network of co-authors of Cynthia Levy

This figure shows the co-authorship network connecting the top 25 collaborators of Cynthia Levy. A scholar is included among the top collaborators of Cynthia Levy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cynthia Levy. Cynthia Levy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Levy, Cynthia, et al.. (2025). Ileal Bile Acid Transport Inhibitors for Cholestatic Pruritus: A Primer. Current Hepatology Reports. 24(1).

Levy, Cynthia, Zobair M. Younossi, Marlyn J. Mayo, et al.. (2025). Assessment of PBC Pruritus From the ITCH ‐E Study: Quality of Life, Productivity, and Treatment Experiences. Liver International. 45(9). e70276–e70276.

Bowlus, Christopher L., Cynthia Levy, Kris V. Kowdley, et al.. (2025). Development of the natural history component of an early economic model for primary sclerosing cholangitis. Orphanet Journal of Rare Diseases. 20(1). 133–133.

Moghe, Akshata, Brendan M. McGuire, & Cynthia Levy. (2024). Acute hepatic porphyrias—A guide for hepatologists. Hepatology. 82(6). 1603–1618. 2 indexed citations

Hussain, Nasir, Christopher Ma, Gideon M. Hirschfield, et al.. (2024). Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis. BMJ Open. 14(6). e080143–e080143. 3 indexed citations

Haq, Zaim, et al.. (2024). Association of Liver Disease and Chronic Pruritus: A Case–Control Study. Liver International. 45(4). e16126–e16126. 3 indexed citations

Bittermann, Therese, Ethan M. Weinberg, Eliot Peyster, et al.. (2024). Real-world evidence for factors associated with maintenance treatment practices among US adults with autoimmune hepatitis. Hepatology. 81(2). 423–435. 2 indexed citations

Invernizzi, Pietro, Marco Carbone, David Jones, et al.. (2023). Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial. Liver International. 43(7). 1507–1522. 37 indexed citations

Trauner, Michael, Chuhan Chung, Xiangyu Liu, et al.. (2023). PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis. BMC Gastroenterology. 23(1). 75–75. 14 indexed citations

10.

Bowlus, Christopher L., Bertus Eksteen, Angela Cheung, et al.. (2023). Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study. Hepatology Communications. 7(6). 22 indexed citations

11.

Kremer, Andreas E., Marlyn J. Mayo, Gideon M. Hirschfield, et al.. (2023). Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology. 80(1). 27–37. 22 indexed citations

12.

Jones, David, Marco Carbone, Pietro Invernizzi, et al.. (2023). Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology Communications. 7(3). e0057–e0057. 22 indexed citations

13.

Levy, Cynthia, Karl E. Anderson, Manisha Balwani, et al.. (2023). PB2562: STUDY DESIGN OF THE AURORA TRIAL: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA. HemaSphere. 7(S3). e904346e–e904346e. 1 indexed citations

14.

Levy, Cynthia, Stuart Kendrick, Christopher L. Bowlus, et al.. (2022). GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus. Clinical Gastroenterology and Hepatology. 21(7). 1902–1912.e13. 50 indexed citations

15.

Kremer, Andreas E., Marlyn J. Mayo, Gideon M. Hirschfield, et al.. (2021). Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver International. 42(1). 112–123. 63 indexed citations

16.

Schattenberg, Jörn M., Albert Parés, Kris V. Kowdley, et al.. (2021). A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology. 74(6). 1344–1354. 125 indexed citations

17.

Eksteen, Bertus, Christopher L. Bowlus, Aldo J. Montaño‐Loza, et al.. (2020). Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. Hepatology Communications. 5(3). 478–490. 35 indexed citations

18.

Firpi, Roberto J., Virginia Clark, Consuelo Soldevila‐Pico, et al.. (2009). The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transplantation. 15(9). 1063–1071. 64 indexed citations

19.

Chahal, Prabhleen, Cynthia Levy, Mark R. Litzow, & Keith D. Lindor. (2006). Utility of liver biopsy in bone marrow transplant patients. Journal of Gastroenterology and Hepatology. 23(2). 222–225. 18 indexed citations

20.

Gordon, Dan, Ian M. Baird, Rabih O. Darouiche, et al.. (1997). Liposomal nystatin (LNY) vs. amphotericin B (AMB) for Candidemia in non-neutropenic patients: A historical comparison. Clinical Infectious Diseases. 25(2). 382. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact